57 results about "Hiv 1 envelope" patented technology

Described are the crystal structure of the alpha-helical domain of the gp41 component of HIV-1 envelope glycoprotein which represents the core of fusion-active gp41, methods of identifying and designing drugs which inhibit gp41 function and drugs which do so.

This invention provides an antibody capable of specifically inhibiting the fusion of an HIV-1 envelope glycoprotein+ cell with an appropriate CD4+ cell without cross reacting with the HIV-1 envelope glycoprotein or CD4 and capable of inhibiting infection by one or more strains of HIV-1. This antibody is then used to identify a molecule which is important for HIV infection. Different uses of the antibody and the molecule are described.

The present application relates to novel HIV-1 envelope glycoproteins, which may be utilized as HIV-1 vaccine immunogens, and antigens for crystallization, electron micrsocopy and other biophysical, biochemical and immunological studies for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions, which are formulated into the vaccines of the present invention.

The present application relates to a novel HIV-1 envelope glycoprotein which may be utilized as an HIV-1 vaccine immunogen, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

The invention discloses a potential preparation method for a highly-efficient recombinant HIV-1 CRF07-BC gp140 immunogen. The immunogen is designed based on the structure of HIV-1 envelope protein crystals which have been published internationally and obtained in our lab. The specific method uses an overlap extension PCR technology to obtain gp140 gene segments, and comprises the steps that target genes are cloned into an eukaryotic expression vector pMT, endotoxin is removed through extraction of a large amount of plasmids, the gp140 gene segments and resistance screening plasmids pCoBlast are co-transfected into drosophila melanogaster Schneider2 (S2) cells together, blasticidin (Blasticidin S) is used for positive clone screening, S2 cell lines for stably and efficiently secreting and expressing gp140 are screened, and after enlarged cultivation and through two steps of purification of nickel column affinity chromatography and gel filtration chromatography, the gp140 with high purity can be obtained. A series of biochemical and biophysical technologies indicate that the gp140 is uniform in polymeric states, and high in antigenic reactivity, and is quite fittingly used as the immunogen for the research and the development of AIDS subunit vaccines or multivalent combined vaccines.

The invention is directed to the use of peptides that can bind and block the interaction of α1 proteinase inhibitor (α1PI) and one or more molecules, for example antibodies to HIV-1 envelope proteins. The invention features methods of activating α1PI in a cell, methods of treating or preventing a disease or disorder in a subject, for example HIV-1 or AIDS. The invention also features pharmaceutical compositions comprising one or more peptides that block the interaction of α1α1PI and one or more molecules. Also included in the invention are kits.

The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.

The present invention relates to modified HIV-1 envelope proteins where one or more N-glycosylation sites have been deleted or modified, which produce a broadly cross reactive neutralizing response, their methods of use and antibodies which bind to these proteins. The invention also provides for nucleic acids, vectors, antibodies and pharmaceutical compositions that comprise said modified HIV-1 envelope proteins.

This invention provides an antibody capable of specifically inhibiting the fusion of an HIV-1 envelope glycoprotein+ cell with an appropriate CD4+ cell without cross reacting with the HIV-1 envelope glycoprotein or CD4 and capable of inhibiting infection by one or more strains of HIV-1. This antibody is then used to identify a molecule which is important for HIV infection. Different uses of the antibody and the molecule are described.

The present application relates to a novel HIV-1 envelope fragments containing the B12 epitope which may be utilized as an HIV-1 vaccine immunogen, in particular for eliciting broad neutralizing antibodies following a prime-boost immunization. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

Methods for immunizing, and immunogen pharmaceutical compositions for eliciting a heterologous immune response to HIV-1 in an animal, preferably a human, are provided, utilizing a modified HIV-1 envelope protein or fragment or DNA encoding a modified HIV-1 envelope protein or fragment, the modified protein having a HIV-1 envelope protein V2 region deletion. A humoral response against heterologous HIV-1 strains is achieved.

The invention provides a recombinant multi-functional chimera of CVN and 12p1. Chimeras of CVN and 12p1 present a model for targeting gp120 at two discrete sites, by two different modes of inhibition and with increasing potency versus either component alone. A chimera of the invention combines the high affinity suppression of viral activity by CVN with the allosteric suppression of viral envelope binding to both CD4 and co-receptor by 12p1.

The present invention relates to HIV-1 envelope proteins from a donor with non-progressive HIV-1 infection whose serum contains broadly cross-reactive, primary virus neutralizing antibody. The invention also relates to isolated or purified proteins and protein fragments that share certain amino acids at particular positions with the foregoing HIV-1 proteins.

The present invention relates, in general, to a formulation suitable for use in inducing anti-HIV-1 antibodies and, in particular, to a formulation comprising a prehairpin intermediate form of HIV-1 envelope gp41 linked to a liposome. The invention also relates to methods of inducing broadly neutralizing anti-HIV-1 antibodies using such a formulation.

The invention relates to the field of biomedicine, relates to an envelope protein trimer immunogen capable of inducing HIV-1 broad spectrum and neutralizing antibody and application thereof, in particular to an envelope protein Env common gene sequence designed based on HIV-1 Chinese epidemic strain and a stable envelope protein gp120 trimer immunogen obtained based on the sequence. The inventionfurther relates to the application of the HIV-1 envelope protein gp120 trimer immunogen in preparation of AIDS vaccines.

The present invention provides compositions and methods useful in the prevention and treatment of HIV-1 infection in a host subject. High affinity binding of an allosteric dual antagonist to HIV-1 gp120 induces a conformational change in the gp 120 protein that traps the gp 120 protein in a three-dimensional structure that suppresses its function and exposes novel antigenic epitopes to host immune surveillance.

Described herein are small-molecule mimics of CD4, which both enter the Phe43 cavity and target Asp368 of gp120, the HIV-1 envelope protein. Also described herein are methods of using these compounds to inhibit the transmission or progression of HIV infection. These compounds exhibit antiviral potency greater than that of a known antiviral, NBD-556, with 100% breadth against clade B and C viruses. Importantly, the compounds do not activate HIV infection of CD4-negative, CCR5-positive cells, in contrast to NBD-556.

Provided herein are HIV vaccines that encompasses recombinant trimers that mimic native HIV-1 envelope trimers. Also provided are methods of administering to a subject in need thereof an HIV vaccine provided herein to elicit antibodies against a recombinant trimer in the subject. A recombinant trimer is formed by a recombinant protein comprising a recombinant HIV-1 gp140 fused to a tag through a linker at C-terminus of the recombinant HIV-1 gp140, wherein the linker is sufficiently long so that the tag is accessible for binding by a binding molecule bound on a solid matrix during purification of the recombinant trimer.

In certain aspects the invention provides a selection of HIV-1 envelopes suitable for use as immunogens, and methods of using these immunogens to induce neutralizing antibodies. In certain embodiments, the immunogens are designed to trimerize. In other embodiments, the immunogenic compositions and methods comprise at least one agent for transient immune response modulation during vaccination.

The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

The present invention relates to HIV-1 envelope proteins from a donor with non-progressive HIV-1 infection whose serum contains broadly cross-reactive, primary virus neutralizing antibody. The invention also relates to isolated or purified proteins and protein fragments that share certain amino acids at particular positions with the foregoing HIV-1 proteins.